In PC, BRCA1 co-regulates the AR activity mediating tumor progression, while BRCA2 limits the metastatic potential of PC by MMP9 downregulation and inhibition of the PI3K/AKT and MAP/ERK pathways (which also regulate PD-L1 expression) [163,164,183,184]. The gene discussed is MMP9; the disease is neoplasm.